四种结构上不同的桑舒尔的保护作用通过恢复肠道屏障功能和调节肠道微生物群来改善德克斯硫酸诱导的性结肠炎
Zhaojun Chen1,2, Hui Wang2, Lulin Tan2
1College of Food Science, Southwest University, Chongqing 400715, China.
Antioxidants (Basel, Switzerland)
|February 24, 2024
概括
来自Zanthoxylum属的Sanshools通过改善肠道屏障功能和微生物群来缓解性结肠炎 (UC). 氧α-sanshool (HAS) 和氧γ-sanshool (HRS) 在这种DSS诱导的大肠炎模型中表现出优异的效果.
科学领域:
- 药理学 药理学 是一个学科.
- 胃肠病学 胃肠病学
- 微生物学 微生物学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病.
- 包括无洞在内的Zanthoxylum属成分具有多样化的药理活动.
- 在炎症条件下,无洞的治疗潜力需要进一步研究.
研究的目的:
- 在小鼠模型中评估四种无洞 (HAS,HBS,HRS,RS) 对硫酸 (DSS) 诱导的性结肠炎 (UC) 的保护作用.
- 阐明潜在的机制,包括抗氧化,抗炎,肠道屏障恢复和微生物群调节.
主要方法:
- 在小鼠中使用DSS诱导UC.
- 四个无洞 (HAS,HBS,HRS,RS) 的管理.
- 评估临床结肠炎症状,结肠长度,组织学损伤,免疫器官体重,抗氧化酶活动,p65 NFκB信号通路,肠道屏障蛋白质和肠道微生物群组成.
主要成果:
- 桑舒尔治疗显著缓解了UC症状,降低了疾病活性指数 (DAI),并改善了结肠长度和完整性.
- Sanshools增强了抗氧化酶活动,RS对总抗氧化能力 (T-AOC) 的影响最小.
- 观察到p65NFκB通路的抑制,肠道屏障功能的恢复 (杯状细胞,紧密结合蛋白) 和肠道微生物群的调节 (拉克诺斯皮拉属,穆里巴库拉属,奥斯基洛斯皮拉属,阿利斯蒂普种的增加;布赫内拉的减少).
- 与氧-β-桑醇 (HBS) 相比,氧-α-桑醇 (HAS) 和氧-γ-桑醇 (HRS) 显示出更显著的改善.
结论:
- 桑舒尔的使用可通过减轻结肠损伤,恢复肠道屏障功能和调节肠道微生物群失调来改善DSS诱导的结肠炎.
- 与HBS相比,HAS和HRS在治疗性结肠炎方面表现出优越的治疗效果.
- 桑舒尔代表了性结肠炎治疗的有前途的治疗策略.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
429
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
429
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
486
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
486
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
436
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
436
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
431
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
431
Peptic Ulcer Disease IV: Management
92
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
92


